JERSEY CITY, N.J.--(BUSINESS WIRE)--Quantum Genomics Corp. (QGC), a global biotech company developing new drugs for metabolic and cardiovascular diseases, announces today a partnership agreement with Inserm, the French national institute for health and medical research and Universities Paris Descartes and Paris XII Val-de-Marne. This is the second lead molecule that QGC is developing through an agreement that brings together some of the leading scientific skills in the field of cardiovascular diseases.
